Nat Biotechnol·· 22 hours agoScore69
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.
In brief
An inhalable exosome system called BEAT co-displays PD-1 and FZD8 in a uniform 1:1 ratio to block PD-L1 and Wnt7b, overexpressed in immune checkpoint inhibitor-resistant melanoma. BEAT recruited and activated CD8+ T cells, reprogramming the tumor microenvironment and producing robust antitumor activity in mouse models of lung metastases, outperforming a linked dual antibody against PD-L1 and Wnt7b in vivo.
Source: Nat Biotechnol · doi.org